Key facts
- This page summarizes Geoffrey M. Parker's Form 4 filing for Allogene Therapeutics, Inc. (ALLO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 23 Oct 2026, 16:48.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Additional SEC filing notes
Footnote F1
Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Footnote F2
Reflects forfeiture of 195,000 shares subject to performance RSUs granted to the Reporting Person on October 10, 2023.
Footnote F3
Includes 12,500 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.
Footnote F4
Includes 11,924 shares of the Issuer's common stock acquired by the reporting person on September 15, 2026 pursuant to an employee stock purchase program.